Year in review: urticaria and angioedema.
Allergy and Immunology, Respiratory Institute, Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: hsiehf@ccf.org.
Fred H
FH
Hsieh
D045930:Anabolic Agents / Q000627:therapeutic use; D054179:Angioedemas, Hereditary / Q000188:drug therapy* / Q000276:immunology; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002762:Cholecalciferol / Q000008:administration & dosage / Q000627:therapeutic use; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein; D019587:Dietary Supplements; D006801:Humans; D000069444:Omalizumab; D011994:Recombinant Proteins / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D014581:Urticaria / Q000188:drug therapy* / Q000276:immunology
D045930:Anabolic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D011994:Recombinant Proteins; C469952:SERPING1 protein, human; D002762:Cholecalciferol; D000069444:Omalizumab; D012460:Sulfasalazine